AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...

AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...

Clinical benefits of the interleukin-33 inhibitor were observed in a broad population, including both former and current smokers, regardless of eosinophil levels. Topline results were announced from ...

Rival treatments had mixed results in the past AstraZeneca sees $3-5 billion peak annual sales for its drug Detailed results to be presented at upcoming medical conference Shares among biggest gainers ...

A blue-chip stock is a stock that comes from a well-known, established company. Blue-chip stocks have a strong history of performance and often pay dividends. Many, or all, of the products featured on ...

Blue Beetle has become a monumental movie for DC and the superhero genre at large: Jaime Reyes is the first official character in James Gunn's new DCU and Blue Beetle marks the first-ever solo film ...